Literature DB >> 25253340

Activation of the RIG-I pathway during influenza vaccination enhances the germinal center reaction, promotes T follicular helper cell induction, and provides a dose-sparing effect and protective immunity.

Raveendra R Kulkarni1, Mohammed Ata Ur Rasheed2, Siddhartha Kumar Bhaumik1, Priya Ranjan3, Weiping Cao3, Carl Davis2, Krishna Marisetti1, Sunil Thomas4, Shivaprakash Gangappa3, Suryaprakash Sambhara5, Kaja Murali-Krishna6.   

Abstract

UNLABELLED: Pattern recognition receptors (PRR) sense certain molecular patterns uniquely expressed by pathogens. Retinoic-acid-inducible gene I (RIG-I) is a cytosolic PRR that senses viral nucleic acids and induces innate immune activation and secretion of type I interferons (IFNs). Here, using influenza vaccine antigens, we investigated the consequences of activating the RIG-I pathway for antigen-specific adaptive immune responses. We found that mice immunized with influenza vaccine antigens coadministered with 5'ppp-double-stranded RNA (dsRNA), a RIG-I ligand, developed robust levels of hemagglutination-inhibiting antibodies, enhanced germinal center reaction, and T follicular helper cell responses. In addition, RIG-I activation enhanced antibody affinity maturation and plasma cell responses in the draining lymph nodes, spleen, and bone marrow and conferred protective immunity against virus challenge. Importantly, activation of the RIG-I pathway was able to reduce the antigen requirement by 10- to 100-fold in inducing optimal influenza-specific cellular and humoral responses, including protective immunity. The effects induced by 5'ppp-dsRNA were significantly dependent on type I IFN and IPS-1 (an adapter protein downstream of the RIG-I pathway) signaling but were independent of the MyD88- and TLR3-mediated pathways. Our results show that activation of the RIG-I-like receptor pathway programs the innate immunity to achieve qualitatively and quantitatively enhanced protective cellular adaptive immune responses even at low antigen doses, and this indicates the potential utility of RIG-I ligands as molecular adjuvants for viral vaccines. IMPORTANCE: The recently discovered RNA helicase family of RIG-I-like receptors (RLRs) is a critical component of host defense mechanisms responsible for detecting viruses and triggering innate antiviral cytokines that help control viral replication and dissemination. In this study, we show that the RLR pathway can be effectively exploited to enhance adaptive immunity and protective immune memory against viral infection. Our results show that activation of the RIG-I pathway along with influenza vaccination programs the innate immunity to induce qualitatively and quantitatively superior protective adaptive immunity against pandemic influenza viruses. More importantly, RIG-I activation at the time of vaccination allows induction of robust adaptive responses even at low vaccine antigen doses. These results highlight the potential utility of exploiting the RIG-I pathway to enhance viral-vaccine-specific immunity and have broader implications for designing better vaccines in general.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25253340      PMCID: PMC4249139          DOI: 10.1128/JVI.02273-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

Review 1.  Ineffective humoral immunity in the elderly.

Authors:  Kiley S McGlauchlen; Laura A Vogel
Journal:  Microbes Infect       Date:  2003-11       Impact factor: 2.700

Review 2.  Immunity to influenza: the challenges of protecting an aging population.

Authors:  Jacqueline M Katz; Julie Plowden; Mary Renshaw-Hoelscher; Xiuhua Lu; Terrence M Tumpey; Suryaprakash Sambhara
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 3.  Germinal centers.

Authors:  Gabriel D Victora; Michel C Nussenzweig
Journal:  Annu Rev Immunol       Date:  2012-01-03       Impact factor: 28.527

4.  Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine.

Authors:  Jeremy M Luke; Gregory G Simon; Jonas Söderholm; John S Errett; J Thomas August; Michael Gale; Clague P Hodgson; James A Williams
Journal:  J Virol       Date:  2010-11-24       Impact factor: 5.103

5.  Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes.

Authors:  Samuele Calabro; Marco Tortoli; Barbara C Baudner; Alessandra Pacitto; Mario Cortese; Derek T O'Hagan; Ennio De Gregorio; Anja Seubert; Andreas Wack
Journal:  Vaccine       Date:  2011-01-06       Impact factor: 3.641

Review 6.  Regulation of plasma-cell development.

Authors:  Miriam Shapiro-Shelef; Kathryn Calame
Journal:  Nat Rev Immunol       Date:  2005-03       Impact factor: 53.106

7.  The novel adjuvant IC31 strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice.

Authors:  Karin Riedl; Rosemarie Riedl; Alexander von Gabain; Eszter Nagy; Karen Lingnau
Journal:  Vaccine       Date:  2008-05-05       Impact factor: 3.641

8.  Optimized lentiviral transduction of mouse bone marrow-derived mesenchymal stem cells.

Authors:  David M Ricks; Robert Kutner; Xian-Yang Zhang; David A Welsh; Jakob Reiser
Journal:  Stem Cells Dev       Date:  2008-06       Impact factor: 3.272

9.  The 3' untranslated regions of influenza genomic sequences are 5'PPP-independent ligands for RIG-I.

Authors:  William G Davis; J Bradford Bowzard; Suresh D Sharma; Mayim E Wiens; Priya Ranjan; Shivaprakash Gangappa; Olga Stuchlik; Jan Pohl; Ruben O Donis; Jacqueline M Katz; Craig E Cameron; Takashi Fujita; Suryaprakash Sambhara
Journal:  PLoS One       Date:  2012-03-15       Impact factor: 3.240

10.  Divergent transcriptional programming of class-specific B cell memory by T-bet and RORα.

Authors:  Nathaniel S Wang; Louise J McHeyzer-Williams; Shinji L Okitsu; Thomas P Burris; Steven L Reiner; Michael G McHeyzer-Williams
Journal:  Nat Immunol       Date:  2012-05-06       Impact factor: 25.606

View more
  35 in total

Review 1.  The regulation of T follicular helper responses during infection.

Authors:  Noah S Butler; Divine I Kulu
Journal:  Curr Opin Immunol       Date:  2015-03-02       Impact factor: 7.486

2.  Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants.

Authors:  Melissa C Hanson; Monica P Crespo; Wuhbet Abraham; Kelly D Moynihan; Gregory L Szeto; Stephanie H Chen; Mariane B Melo; Stefanie Mueller; Darrell J Irvine
Journal:  J Clin Invest       Date:  2015-05-04       Impact factor: 14.808

3.  RIG-I ligand enhances the immunogenicity of recombinant H7HA protein.

Authors:  Weiping Cao; Justine S Liepkalns; Ram P Kamal; Adrian J Reber; Jin Hyang Kim; Amelia R Hofstetter; Samuel Amoah; James Stevens; Priya Ranjan; Shivaprakash Gangappa; Ian A York; Suryaprakash Sambhara
Journal:  Cell Immunol       Date:  2016-04-09       Impact factor: 4.868

Review 4.  Antigen presentation by dendritic cells and their instruction of CD4+ T helper cell responses.

Authors:  Kerry L Hilligan; Franca Ronchese
Journal:  Cell Mol Immunol       Date:  2020-05-20       Impact factor: 11.530

5.  Sequence-Specific Modifications Enhance the Broad-Spectrum Antiviral Response Activated by RIG-I Agonists.

Authors:  Cindy Chiang; Vladimir Beljanski; Kevin Yin; David Olagnier; Fethia Ben Yebdri; Courtney Steel; Marie-Line Goulet; Victor R DeFilippis; Daniel N Streblow; Elias K Haddad; Lydie Trautmann; Ted Ross; Rongtuan Lin; John Hiscott
Journal:  J Virol       Date:  2015-05-27       Impact factor: 5.103

6.  Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors.

Authors:  Tyrel T Smith; Howell F Moffett; Sirkka B Stephan; Cary F Opel; Amy G Dumigan; Xiuyun Jiang; Venu G Pillarisetty; Smitha P S Pillai; K Dane Wittrup; Matthias T Stephan
Journal:  J Clin Invest       Date:  2017-04-24       Impact factor: 14.808

Review 7.  Strategies to guide the antibody affinity maturation process.

Authors:  Nicole A Doria-Rose; M Gordon Joyce
Journal:  Curr Opin Virol       Date:  2015-04-24       Impact factor: 7.090

8.  Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.

Authors:  Vladimir Beljanski; Cindy Chiang; Greg A Kirchenbaum; David Olagnier; Chalise E Bloom; Terianne Wong; Elias K Haddad; Lydie Trautmann; Ted M Ross; John Hiscott
Journal:  J Virol       Date:  2015-08-12       Impact factor: 5.103

9.  MAVS Is Essential for Primary CD4+ T Cell Immunity but Not for Recall T Cell Responses following an Attenuated West Nile Virus Infection.

Authors:  Huanle Luo; Evandro Winkelmann; Guorui Xie; Rong Fang; Bi-Hung Peng; Li Li; Helen M Lazear; Slobodan Paessler; Michael S Diamond; Michael Gale; Alan D Barrett; Tian Wang
Journal:  J Virol       Date:  2017-02-28       Impact factor: 5.103

10.  TLR7 and RIG-I dual-adjuvant loaded nanoparticles drive broadened and synergistic responses in dendritic cells in vitro and generate unique cellular immune responses in influenza vaccination.

Authors:  Randall Toy; M Cole Keenum; Pallab Pradhan; Katelynn Phang; Patrick Chen; Chinwendu Chukwu; Lily Anh H Nguyen; Jiaying Liu; Sambhav Jain; Gabrielle Kozlowski; Justin Hosten; Mehul S Suthar; Krishnendu Roy
Journal:  J Control Release       Date:  2020-11-05       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.